US private equity firm TA Associates has confirmed it is in active takeover discussions with Advanced Medical Solutions Group (LON: AMS), the Cheshire-based tissue-healing technology company, with a potential offer of around 280 pence per share that would value the Business at more than £600 million and represent a substantial premium to where the stock was trading before the bid emerged.
Advanced Medical Solutions issued a regulatory statement on April 20 confirming it was in discussions with TA after Sky News first reported the approach at the weekend, triggering a sharp jump in the shares, which had been trading at 228 pence on Friday, giving the company a market capitalisation of around £500 million before the news surfaced.
The AIM-listed group, which manufactures surgical products under brands including LiquiBand, Resorba, LiquiBandFix8 and ActivHeal, confirmed it has entered a formal offer period under UK Takeover Code rules, meaning TA Associates must either announce a firm intention to make an offer or walk away by 5 p.m. on May 16, 2026, a 28-day deadline from Monday’s announcement.
The company has made clear there is no certainty a formal offer will materialise, nor that terms have been agreed, but the language of the announcement confirms that discussions are substantive and ongoing rather than exploratory.
The backdrop for the potential deal is a markedly improved fundamental picture. Advanced Medical Solutions reported a pretax profit of £17.8 million in 2025, an 81 percent increase from the £9.8 million delivered the year prior, a result that reflects strong performance in its Surgical segment and steady growth across wound care. The stock has gained around 25 percent over the past twelve months even before this week’s bid premium was applied.
TA Associates’ interest is part of a wider pattern of overseas private equity firms targeting London-listed companies, particularly in the life sciences and medtech space, where UK equity valuations have remained relatively low compared to comparable businesses listed in the United States or on European bourses. Previous suitors for the company have included Montagu, Inflexion and Bridgepoint, according to market reports, indicating a track record of attracting strategic interest.
Advanced Medical Solutions’ board has said it is being advised on the approach, and shareholders are in a formal dealing disclosure period for the duration of the offer window. The company’s Boston, Massachusetts-based potential acquirer is one of the most active growth-oriented PE firms in the healthcare technology space globally, with a portfolio spanning software, healthcare IT and life sciences.